Pricing Log in Create free account

BridgeBio Oncology Therapeutics, Inc (BBOT) vs Lineage Cell Therapeutics, Inc. (LCTX)

BridgeBio Oncology Therapeutics, Inc and Lineage Cell Therapeutics, Inc. are both Biotechnology companies. BridgeBio Oncology Therapeutics, Inc and Lineage Cell Therapeutics, Inc. are of similar size ($250.5M and $236.5M). BridgeBio Oncology Therapeutics, Inc has the higher net margin (0.00% vs −246.6%) and the higher return on invested capital (−127.7% vs −186.8%). Across the 13 metrics below, BridgeBio Oncology Therapeutics, Inc leads on 7 and Lineage Cell Therapeutics, Inc. on 6.

Valuation

Metric BBOT LCTX Biotechnology median
P/E n/m n/m 8.50
P/S n/m 18.69 9.71
P/B 0.70 4.09 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 14.81 9.21
Earnings yield (97.87%) (14.67%) (33.15%)
Free cash flow yield (67.14%) (9.98%) (25.50%)

Profitability

Metric BBOT LCTX Biotechnology median
Gross margin — 99.46% 65.16%
Operating margin 0.00% (205.23%) 0.00%
Net margin 0.00% (246.58%) 0.00%
Free cash flow margin 0.00% (186.43%) 0.00%
Return on equity (252.10%) (60.35%) (56.36%)
Return on assets (96.69%) (32.75%) (48.04%)
Return on invested capital (127.66%) (186.79%) 0.00%

Growth

Metric BBOT LCTX Biotechnology median
Revenue growth (TTM) — 19.87% 6.02%
EPS growth (last fiscal year) 99.93% (211.11%) 30.26%
Revenue growth, 5-year CAGR — 51.46% 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BBOT LCTX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.69 6.61 4.72
Net debt to EBITDA 2.93 2.64 0.96

Dividend

Metric BBOT LCTX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BBOT LCTX Biotechnology median
Market cap 236.52m 250.45m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack